NEW YORK, April 1, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ:
ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ:
ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Gilead Sciences, Inc. Analyst Notes
On March 27, 2014, Gilead
Sciences, Inc. (Gilead) announced that its Marketing Authorization
Application (MAA) for a once-daily fixed-dose combination of the
NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog
polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of
chronic hepatitis C virus (HCV) genotype 1 infection has been fully
validated and is currently under assessment by the European
Medicines Agency (EMA). "Based on the results of the Phase 3 ION
studies, LDV/SOF has the potential to transform HCV therapy for
genotype 1 patients by eliminating the need for interferon
injections and ribavirin and reducing the duration of treatment,"
said Norbert Bischofberger, PhD,
Executive Vice President of Research and Development and Chief
Scientific Officer at Gilead. "If approved, LDV/SOF would be the
first all-oral treatment option that has the potential to cure HCV
in as little as eight weeks." The full analyst notes on Gilead
Sciences, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04012014/GILD/report.pdf
--
Enzymotec Ltd. Analyst Notes
On March 5, 2014, Enzymotec Ltd.
(Enzymotec) announced the closing of a registered public offering
by certain selling shareholders of 5.4 million ordinary shares at
$28.00 per share, including 0.7
million shares purchased pursuant to the full exercise of the
underwriters' option to purchase additional shares. The Company
noted that it did not receive any proceeds from the sale of these
shares. The full analyst notes on Enzymotec Ltd. are available to
download free of charge at:
http://www.AnalystsReview.com/04012014/ENZY/report.pdf
--
Intrexon Corporation Analyst Notes
On March 27, 2014, Intrexon
Corporation (Intrexon) announced the formation of Intrexon Energy
Partners (IEP), a joint venture with a select group of external
investors. The Company noted that IEP aims to optimize and scale-up
Intrexon's gas-to-liquid (GTL) bioconversion platform for the
production of fuels and lubricants. The Company further explained
that IEP's first target product is isobutanol for gasoline
blending. "As our first partnered endeavor in the Energy Sector,
the formation of IEP exemplifies investor confidence in the power
of our integrated synthetic biology platforms beyond our
established health, food, and consumer capabilities," said
Randal J. Kirk, Chairman and CEO of
Intrexon. "We envision IEP building upon Intrexon's biocatalyst
platform to produce additional high-value fuels and lubricants
beyond isobutanol." The full analyst notes on Intrexon Corporation
are available to download free of charge at:
http://www.AnalystsReview.com/04012014/XON/report.pdf
--
Advaxis, Inc. Analyst Notes
On March 24, 2014, Advaxis, Inc.
(Advaxis) announced the appointment of Sara
Bonstein to the position of CFO and Senior Vice President.
Prior to joining the Company, Bonstein worked at Eli Lilly &
Company. "Sara's significant financial experience across multiple
biopharmaceutical sectors will be a great asset to Advaxis," said
Daniel J. O'Connor, President and
CEO of Advaxis. O'Connor added, "She is a seasoned financial leader
in the biopharmaceutical industry and, importantly, has
demonstrated the ability to lead budget and forecast activities for
clinical R&D and manufacturing, which is crucial to our growth.
She has been successful in building and managing world class
finance teams at significant public biopharmaceutical corporations.
Sara's strong operational experience in systems development,
budget, forecasting, clinical, and regulatory affairs will be
invaluable as we continue to grow Advaxis." The full analyst notes
on Advaxis, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04012014/ADXS/report.pdf
--
Repligen Corporation Analyst Notes
On March 26, 2014, Repligen
Corporation (Repligen) announced the commercial launch of its OPUS®
45 cm diameter columns (OPUS 45) with the largest capacity
currently available on the market. The Company noted that OPUS 45
aims to process large single-use bioreactor harvests. "Since
launching process scale OPUS columns in 2012, our biopharmaceutical
customers have embraced our "any resin, any size" approach which
offers the most flexibility among run-ready chromatography
options," said Steve Tingley, Vice
President of Bioprocessing Sales & Marketing for Repligen.
"Since then, our customers have requested OPUS columns that are
capable of processing harvests from larger disposable fermentors
for producing clinical-stage drug candidates and niche commercial
biologics. In response we are introducing OPUS 45 and have already
begun to fulfill orders." The full analyst notes on Repligen
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04012014/RGEN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review